STOCK TITAN

Verano Announces Third Quarter 2022 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Positive)
Tags
Rhea-AI Summary

Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) reported a strong Q3 2022, with revenue reaching $228 million, a 10% increase year-over-year driven by adult use sales in New Jersey. Gross profit improved to 54% of revenue, up from 48% the previous year. However, net loss widened to $(43) million. Adjusted EBITDA was $82 million, or 36% of revenue. Operationally, Verano expanded with new dispensaries in Florida and launched new products. The refinancing of a $350 million credit facility provides financial flexibility.

Positive
  • Q3 2022 revenue increased 10% year-over-year to $228 million.
  • Gross profit margin improved to 54% vs. 48% last year.
  • Adjusted EBITDA increased to $82 million, or 36% of revenue.
  • Expanded retail presence with 11 new MÜV dispensaries in Florida.
Negative
  • Widened net loss of $(43) million, compared to $(13) million last year.
  • Working capital deficit of $(89) million.
  • Total debt increased to $392 million.

CHICAGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (CSE: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced its financial results for the third quarter ended September 30, 2022 (“Q3 2022"), which were prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”). Comparable numbers for the third quarter ended September 30, 2021 (“Q3 2021”) were also prepared in accordance with U.S. GAAP.

2022 Third Quarter Financial Highlights

• Q3 2022 revenue increased 2% versus the prior quarter and 10% year-over-year to $228 million.
◦ Revenue growth versus the year-ago period was driven by strength from adult use sales in New Jersey.
• Q3 2022 gross profit was $123 million or 54% of revenue, compared to $98 million or 44% of revenue in the prior quarter, and $98 million or 48% of revenue in the third quarter 2021.
◦ Gross profit growth versus the year-ago period was driven by top-line growth and a lower comparative impact related to the inventory step-up from acquisitions.
• Q3 2022 SG&A was $86 million or 38% of revenue, compared to $100 million or 45% of revenue in the prior quarter, and $76 million or 37% of revenue in the third quarter 2021.
◦ SG&A growth versus the year-ago period was primarily driven by an increase in retail locations.
• Q3 2022 net loss was $(43) million, compared to a loss of $(10) million in the prior quarter, and $(13) million in the year-ago period.
• Adjusted EBITDA1 was $82 million or 36% of revenue, compared to Adjusted EBITDA of $76 million or 34% of revenue in the prior quarter.
• Cash flow from operations for the nine months ended September 30, 2022 was $65 million.

2022 Third Quarter Operational Highlights
• Furthered Florida retail expansion by opening 11 new MÜV dispensaries across the state throughout the quarter.
• Opened new Zen Leaf dispensaries in Wheeling and Clarksburg, WV, and New Kensington, PA; relocated Zen Leaf Jessup to Elkridge in Maryland to optimized location and retail space; maximized New Jersey footprint with the commencement of adult use sales at Zen Leaf Neptune on the Jersey Shore.
• Launched Verano signature flower branded products in four new core markets – Arizona, Florida, Massachusetts and Pennsylvania; Verano signature flower branded products are now distributed to more than 500 dispensaries across nine states, including more than 100 of the Company’s retail locations.
• Introduced Savvy, a new flower and extract brand featuring larger-format cannabis products that caters to more value-oriented patients and consumers, across seven core markets.
• Inked licensing agreement with Mike Tyson's Tyson 2.0 cannabis company to launch legendary wrestler Ric Flair's new cannabis line, Ric Flair Drip Cannabis, across 11 markets.
• Welcomed Lawrence Hirsh as a new member of the Board of Directors and Chair of the Audit Committee.
• Completed acquisition of Sierra Well, bolstering Nevada footprint with addition of two operating dispensaries and an active cultivation facility.
• Initiated second annual Breast Cancer Awareness Month donation effort benefiting the Lynn Sage Breast Cancer Foundation.

Subsequent Operational Highlights

• Refinanced $350M credit facility with enhanced flexibility to reduce capital costs.
• Opened two new MÜV dispensary locations in Panama City Beach and Port Orange, Florida, raising the Company's Florida retail footprint to 61 locations.
• Launched BITS, a new brand and product line consisting of five unique flavors of low-dose, high-function edibles that blend THC, cannabinoids and adaptogens, appealing to cannabis enthusiasts of all experience levels.
• Active operations span 13 states, comprised of 119 dispensaries and 14 cultivation and processing facilities with more than 1 million square feet of cultivation capacity. 

Management Commentary
“I am very pleased with our performance in the third quarter and how our team demonstrated focus and adaptability in driving our business forward in an increasingly challenging environment,” said George Archos, Verano Founder, Chairman and Chief Executive Officer. “In the face of economic headwinds, industry dynamics and legislative uncertainty, we delivered revenue growth and strong Adjusted EBITDA margins, underscoring our focus on superior operations and efficiency. We significantly bolstered our growing product portfolio by scaling our signature Verano brand across core markets, introducing our value flower and extract brand Savvy, launching Ric Flair’s Ric Flair Drip Cannabis line in partnership with Tyson 2.0, and most recently, releasing a low-dose, high-function edibles line, BITS, which combine tailored adaptogens with cannabinoids and 5 mg of THC to appeal to a broad base of cannabis consumers. We also continue to see positive results in New Jersey, where we’ve further cemented our position as a market leader, evidenced by our strong retail performance and growing wholesale business. Finally, we are also pleased to have completed the refinancing of our $350 million credit facility, which gives us flexibility in our capital structure and the ability to reduce our cost of capital. I remain optimistic and confident in our business as we continue to maintain focus on driving operational quality and efficiency as we further position Verano for future growth.”

Balance Sheet and Liquidity
As of September 30, 2022, the Company’s current assets were $295 million, including cash and cash equivalents of $76 million. The Company had working capital deficit of $(89) million and total debt, net of issuance costs, of $392 million.

The Company’s total Class A subordinate voting shares outstanding, including Class B proportionate voting shares on an as-converted to Class A subordinate voting share basis, was 336,162,222 as of September 30, 2022.

Non-U.S. GAAP Financial Measures
Verano uses non-U.S. GAAP financial information to evaluate the performance of the Company. The terms “EBIT,” “EBITDA” and “Adjusted EBITDA” do not have any standardized meaning prescribed within U.S. GAAP and therefore may not be comparable to similar measures presented by other companies. Accordingly, this non-U.S. GAAP financial information is intended to provide additional information and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with U.S. GAAP.

The Company calculates EBIT as net earnings from operations before interest expense and tax expenses, EBITDA as net earnings from operations before interest expense, tax expense, depreciation, and amortization and Adjusted EBITDA as EBITDA as adjusted for one-time expenses related to other expenses, employee stock compensation, gain from investment in associates, acquisition, transaction and other non-operating costs and acquisition adjustments and other income (expense), net. The calculations of the non-U.S. GAAP financial measures used in this news release and the reconciliations to the most comparable U.S. GAAP financial numbers are included in the tables below.

Management believes that this non-U.S. GAAP financial information is useful as a supplement to comparable U.S. GAAP financial information. Management reviews these non-U.S. GAAP financial measures on a regular basis and uses them, together with financial measures included in the Company’s financial statements, to evaluate and manage the performance of the Company’s operations. These measures should be evaluated only in conjunction with the comparable U.S. GAAP financial numbers reported by the Company.

Conference Call and Webcast

A conference call and audio webcast with analysts and investors will be held on November 14, 2022 at 8:30 a.m. ET / 7:30 a.m. CT to discuss the results and answer investor and participant questions.

About Verano
Verano is a leading, vertically integrated, multi-state cannabis operator in the U.S., devoted to the ongoing improvement of communal wellness by providing responsible access to regulated cannabis products. With a mission to address vital health and wellness needs, Verano produces a comprehensive suite of premium, innovative cannabis products sold under its trusted portfolio of consumer brands, including Verano, Avexia, BITS, Encore, MŪV and Savvy. Verano’s portfolio encompasses 14 U.S. states, with active operations in 13, including 14 production facilities comprising over 1,000,000 square feet of cultivation capacity. Verano designs, builds, and operates dispensaries under retail brands including Zen Leaf and MŪV, delivering a superior cannabis shopping experience in both medical and adult use markets. Learn more at www.verano.com.

Contacts:
Investors
Verano
Julianna Paterra, CFA
Director, Investor Relations
julianna.paterra@verano.com

Media
Verano
Steve Mazeika
Director, Communications
steve.mazeika@verano.com
312-348-4430

Forward Looking Statements

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “future”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. Forward-looking statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking statements herein, including, without limitation, the risk factors described in the Company’s registration statement on Form 10, as amended, and quarterly reports on Form 10-Q filed with the U.S. Securities and Exchange Commission at www.sec.gov. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information or forward-looking statements that are contained or referenced herein, except as may be required in accordance with applicable securities laws. All subsequent written and oral forward-looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice regarding forward-looking information and statements.

Financial Information Tables

The following tables includes the reconciliations of the non-U.S. GAAP financial measures to the respective most directly comparable U.S. GAAP financial measures for the three months ended June 30, 2022 and the three and nine months ended September 30, 2022 and September 30, 2021.

VERANO HOLDINGS CORP.
Highlights from Unaudited Consolidated Statements of Operations
($ in Thousands except share and per share amounts)

  Three Months Ended September 30,  Nine Months Ended September 30, 
  2022  2021  2022  2021 
Revenue $227,588  $206,469  $653,485  $526,430 
Cost of Sales  104,594   108,268   333,759   304,729 
Gross Profit  122,994   98,201   319,726   221,701 
Gross Profit %  54.0%  47.6%  48.9%  42.1%
Expenses:                
Selling, General, and Administrative  85,710   76,477   275,531   189,155 
Total Expenses  85,710   76,477   275,531   189,155 
Income (Loss) from Investments in Associates  (209)  1,289   1,651   2,737 
Income (Loss) from Operations  37,075   23,013   45,846   35,283 
Other Income (Expense):                
Loss on Disposal of Property, Plant and Equipment  1,443   (9)  251   (438)
Gain (Loss) on Deconsolidation  75      9,560    
Gain (Loss) on Previously Held Equity Interest  175      14,103    
Interest Expense, net  (595)  233   17,557   (764)
Other Income (Expense), net  (11,785)  (8,113)  (34,082)  (15,314)
Total Other Income (Expense)  (10,687)  (7,889)  7,389   (16,516)
Net Income (Loss) Before Provision for Income Taxes and Non-Controlling Interest  26,388   15,124   53,235   18,767 
Provision For Income Taxes  (69,381)  (27,086)  (105,998)  (66,939)
Net Income Attributable To Non-Controlling Interest     551   291   1,915 
Net Loss Attributable to Verano Holdings Corp.  (42,993)  (12,513)  (53,054)  (50,087)
Net Loss per share - basic  (0.13)  (0.04)  (0.16)  (0.18)
Net Loss per share - diluted  (0.13)  (0.04)  (0.16)  (0.18)
Weighted average number of shares outstanding - basic  332,872,464   313,674,044   329,240,200   281,961,659 
Weighted average number of shares outstanding - diluted  332,872,464   313,674,044   329,240,200   281,961,659 


VERANO HOLDINGS CORP.

Highlights from Unaudited Consolidated Statements of Operations (Continued)
($ in Thousands except share and per share amounts)

  Three Months Ended June 30, 2022 
Revenue $223,662 
Cost of Sales  125,547 
Gross Profit  98,115 
Gross Profit %  43.9%
Expenses:    
Selling, General, and Administrative  100,263 
Total Expenses  100,263 
Income (Loss) from Investments in Associates  (144)
Income (Loss) from Operations  (2,292)
Other Income (Expense):    
Loss on Disposal of Property, Plant and Equipment  (203)
Gain (Loss) on Deconsolidation  (73)
Gain (Loss) on Previously Held Equity Interest  (171)
Interest Expense, net  (11,624)
Other Income (Expense), net  15,619 
Total Other Income (Expense)  3,548 
Net Income (Loss) Before Provision for Income Taxes and Non-Controlling Interest  1,256 
Provision For Income Taxes  (11,103)
Net Income Attributable To Non-Controlling Interest   
Net Loss Attributable to Verano Holdings Corp.  (9,847)
Net Loss per share - basic  (0.03)
Net Loss per share - diluted  (0.03)
Weighted average number of shares outstanding - basic  328,519,193 
Weighted average number of shares outstanding - diluted  328,519,193 


VERANO HOLDINGS CORP.

Highlights from Condensed Consolidated Balance Sheets
($ in Thousands)

  September 30,  December 31, 
  2022  2021 
  (Unaudited)  (As Restated) 
Cash and Cash Equivalents $76,418  $99,118 
Other Current Assets  218,652   177,926 
Property and Equipment, Net  533,753   452,232 
Intangible Assets, Net  1,326,601   1,379,913 
Goodwill  380,408   368,130 
Other Long-Term Assets  87,195   71,336 
Total Assets $2,623,027  $2,548,655 
         
Total Current Liabilities $384,197  $470,516 
Total Long-Term Liabilities  698,536   596,333 
Total Shareholders' Equity  1,540,294   1,480,530 
Non-controlling Interest $   1,276 
Total Liabilities and Shareholders' Equity $2,623,027  $2,548,655 


VERANO HOLDINGS CORP.

Unaudited Reconciliation of Net Loss to EBITDA (Non-U.S. GAAP)

($ in thousands) Three Months Ended
September 30,
  Nine Months Ended
September 30,
 
  2022  2021  2022  2021 
Net Loss Attributable to Verano Holdings Corp. $(42,993) $(12,513) $(53,054) $(50,087)
Interest Expense, net  11,785   8,113   34,082   15,314 
Income Tax Expense  69,381   27,086   105,998   66,939 
Depreciation and Amortization - COGS  20,727   16,083   59,540   38,365 
Depreciation and Amortization - SG&A  15,592   13,481   46,690   27,255 
Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)  74,492   52,250   193,256   97,786 

($ in thousands) Three Months Ended June 30, 2022 
Net Loss Attributable to Verano Holdings Corp. $(9,847)
Interest Expense, net  11,624 
Income Tax Expense  11,103 
Depreciation and Amortization - COGS  19,089 
Depreciation and Amortization - SG&A  16,388 
Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)  48,357 


VERANO HOLDINGS CORP.

Unaudited Reconciliation of Net Loss to EBIT (Non-U.S. GAAP) and Adjusted EBITDA (Non-U.S. GAAP)

($ in thousands) Three Months Ended September 30,  Nine Months Ended September 30, 
  2022  2021  2022  2021 
Net Loss Attributable to Verano Holdings Corp. $(42,993) $(12,513) $(53,054) $(50,087)
Interest Expense, Net  11,785   8,113   34,082   15,314 
Income Tax Expense  69,381   27,086   105,998   66,939 
Earnings Before Interest and Taxes (EBIT) $38,173  $22,686  $87,026  $32,166 
                 
COGS Add-backs:                
Depreciation and Amortization  20,727   16,083   59,540   38,365 
Acquisition, Transaction and Other Non-operating Costs  111   30,419   20,108   84,223 
Employee Stock Compensation  1,745   1,486   5,772   1,486 
                 
SG&A Add-backs:                
Depreciation and Amortization  15,592   13,481   46,690   27,255 
Acquisition, Transaction and Other Non-operating Costs  (1,791)  4,671   21,181   27,987 
Employee Stock Compensation  8,075   11,903   28,452   30,236 
                 
Acquisition Adjustments and Other Income (Expense), net $(508) $209  $(23,916) $630 
                 
Adjusted EBITDA $82,124  $100,938  $244,853  $242,348 


VERANO HOLDINGS CORP.
Unaudited Reconciliation of Net Loss to EBIT (Non-U.S. GAAP) and Adjusted EBITDA (Non-U.S. GAAP) (Continued)

($ in thousands) Three Months Ended June 30, 2022 
Net Loss Attributable to Verano Holdings Corp. $(9,847)
Interest Expense, Net  11,624 
Income Tax Expense  11,103 
Earnings Before Interest and Taxes (EBIT) $12,880 
     
COGS Add-backs:    
Depreciation and Amortization  19,089 
Acquisition, Transaction and Other Non-operating Costs  15,385 
Employee Stock Compensation  2,976 
     
SG&A Add-backs:    
Depreciation and Amortization  16,388 
Acquisition, Transaction and Other Non-operating Costs  10,720 
Employee Stock Compensation  10,515 
     
Acquisition Adjustments and Other Income (Expense), net  (12,428)
     
Adjusted EBITDA $75,526 

1 Adjusted EBITDA is a non-U.S. GAAP financial measure. It is derived from EBITDA, another non-U.S. GAAP financial measure, and is defined in this news release in the section below titled “Non-U.S. GAAP Financial Measures.” The most comparable U.S. GAAP financial measure to Adjusted EBITDA net income. The reconciliation of Adjusted EBITDA to U.S. GAAP net income is set forth below in the tables included in this news release.


FAQ

What were Verano's Q3 2022 financial results?

Verano reported Q3 2022 revenue of $228 million, a 10% increase year-over-year, with a net loss of $(43) million and adjusted EBITDA of $82 million.

What drove the revenue growth for Verano in Q3 2022?

Revenue growth was primarily driven by strength in adult use sales in New Jersey.

How many dispensaries does Verano operate as of Q3 2022?

As of Q3 2022, Verano operates 119 dispensaries across 13 states.

What is Verano's strategy for product expansion?

Verano is expanding its product offerings with new brands such as Savvy and the Ric Flair Drip Cannabis line.

What is the status of Verano's debt as of Q3 2022?

Verano has total debt of $392 million and a working capital deficit of $(89) million.

VERANO HLDGS CORP

OTC:VRNOF

VRNOF Rankings

VRNOF Latest News

VRNOF Stock Data

610.70M
302.30M
15.59%
10.6%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Chicago